Tc Biopharm Holdings Stock Performance
| TCBP Stock | USD 1.95 0.22 10.14% |
The firm owns a Beta (Systematic Risk) of -0.92, which indicates possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning TC BioPharm are expected to decrease slowly. On the other hand, during market turmoil, TC BioPharm is expected to outperform it slightly. At this point, TC BioPharm Holdings has a negative expected return of -2.07%. Please make sure to validate TC BioPharm's information ratio, as well as the relationship between the potential upside and rate of daily change , to decide if TC BioPharm Holdings performance from the past will be repeated sooner or later.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days TC BioPharm Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's fundamental drivers remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Last Split Factor 1:10 | Last Split Date 2024-08-05 |
1 | TCBP Provides Quarterly Update on the ACHIEVE Clinical Trial | 12/04/2024 |
2 | EXCLUSIVE Penny Stock TC BioPharm Proposes Special Stock Dividend | 12/18/2024 |
3 | TCBP Advances ACHIEVE Phase 2b Clinical Trial with Final Dosing of 3 Patients | 12/20/2024 |
4 | TCBP Provides Update on Acquisition Strategy and Current Targets | 12/31/2024 |
5 | TC Biopharm Faces Potential Nasdaq Delisting Due to Bid Price Non-Compliance - TipRanks | 01/08/2025 |
6 | Discretionary transaction by Randall Kenneth Edward of 5306464 shares of TC BioPharm at 4.25 subject to Rule 16b-3 | 01/27/2025 |
7 | Acquisition by Randall Diana Elizabeth of 70000 shares of TC BioPharm subject to Rule 16b-3 | 01/29/2025 |
8 | EXCLUSIVE Nano-Cap TC BioPharm Concludes Initial Cohort B Patient Dosing In Mid-Stage Leukemia Trial, Data Readout By End Of 2025 | 02/10/2025 |
9 | TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum | 02/20/2025 |
| Begin Period Cash Flow | 4.8 M | |
| Free Cash Flow | -10.7 M |
TCBP |
TC BioPharm Relative Risk vs. Return Landscape
If you would invest 950.00 in TC BioPharm Holdings on December 1, 2024 and sell it today you would lose (755.00) from holding TC BioPharm Holdings or give up 79.47% of portfolio value over 90 days. TC BioPharm Holdings is currently does not generate positive expected returns and assumes 10.3461% risk (volatility on return distribution) over the 90 days horizon. In different words, 92% of stocks are less volatile than TCBP, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
TC BioPharm Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for TC BioPharm's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as TC BioPharm Holdings, and traders can use it to determine the average amount a TC BioPharm's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2003
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TCBP |
Estimated Market Risk
| 10.35 actual daily | 92 92% of assets are less volatile |
Expected Return
| -2.07 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.2 actual daily | 0 Most of other assets perform better |
Based on monthly moving average TC BioPharm is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of TC BioPharm by adding TC BioPharm to a well-diversified portfolio.
TC BioPharm Fundamentals Growth
TCBP Stock prices reflect investors' perceptions of the future prospects and financial health of TC BioPharm, and TC BioPharm fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on TCBP Stock performance.
| Return On Equity | -12.17 | ||||
| Return On Asset | -1.09 | ||||
| Current Valuation | 1.92 M | ||||
| Shares Outstanding | 572.02 K | ||||
| Price To Book | 0.43 X | ||||
| Price To Sales | 0.51 X | ||||
| Gross Profit | 3.84 M | ||||
| EBITDA | (13.61 M) | ||||
| Net Income | (5.91 M) | ||||
| Cash And Equivalents | 1.57 M | ||||
| Cash Per Share | 0.08 X | ||||
| Total Debt | 1.8 M | ||||
| Current Ratio | 0.19 X | ||||
| Book Value Per Share | 3.38 X | ||||
| Cash Flow From Operations | (10.54 M) | ||||
| Earnings Per Share | (192.95) X | ||||
| Market Capitalization | 360.37 K | ||||
| Total Asset | 8.93 M | ||||
| Retained Earnings | (38.84 M) | ||||
| Working Capital | 950.33 K | ||||
About TC BioPharm Performance
Assessing TC BioPharm's fundamental ratios provides investors with valuable insights into TC BioPharm's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the TC BioPharm is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.64) | (0.67) | |
| Return On Capital Employed | (3.92) | (4.11) | |
| Return On Assets | (0.60) | (0.62) | |
| Return On Equity | (2.53) | (2.40) |
Things to note about TC BioPharm Holdings performance evaluation
Checking the ongoing alerts about TC BioPharm for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for TC BioPharm Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| TC BioPharm Holdings generated a negative expected return over the last 90 days | |
| TC BioPharm Holdings has high historical volatility and very poor performance | |
| TC BioPharm Holdings may become a speculative penny stock | |
| TC BioPharm Holdings has a very high chance of going through financial distress in the upcoming years | |
| TC BioPharm Holdings currently holds 1.8 M in liabilities. TC BioPharm Holdings has a current ratio of 0.19, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about TC BioPharm's use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (5.91 M) with profit before overhead, payroll, taxes, and interest of 3.84 M. | |
| TC BioPharm Holdings currently holds about 1.57 M in cash with (10.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08. | |
| TC BioPharm Holdings has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum |
- Analyzing TC BioPharm's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether TC BioPharm's stock is overvalued or undervalued compared to its peers.
- Examining TC BioPharm's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating TC BioPharm's management team can have a significant impact on its success or failure. Reviewing the track record and experience of TC BioPharm's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of TC BioPharm's stock. These opinions can provide insight into TC BioPharm's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for TCBP Stock Analysis
When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.